GLP-1s may nearly halve risk for hepatic complications in MASLD, type 2 diabetes

Use of GLP-1s was associated with significantly reduced risk for hepatic complications among patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes, according to data.The observational study, published in The American Journal of Gastroenterology, showed that the reduction was prompted by fewer cases of incident cirrhosis. Researchers also found that GLP-1s may